- Home
- NODK vs INAB Comparison
NODK vs INAB Comparison
Compare NODK & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NODK | INAB |
|---|---|---|
| Founded | 1946 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 278.8M | 10.6M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NODK | INAB |
|---|---|---|
| Price | $13.53 | $2.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $108.00 |
| AVG Volume (30 Days) | 16.3K | ★ 664.6K |
| Earning Date | 11-07-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $297,973,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $122.94 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.01 | $1.17 |
| 52 Week High | $16.25 | $12.53 |
Technical Indicators
Market Signals| Indicator | NODK | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 44.69 | 66.12 |
| Support Level | $13.39 | $1.17 |
| Resistance Level | $14.13 | $1.87 |
| Average True Range (ATR) | 0.48 | 0.21 |
| MACD | -0.07 | 0.06 |
| Stochastic Oscillator | 17.00 | 96.26 |
Price Performance
Historical ComparisonAbout NODK NI Holdings Inc.
NI Holdings Inc is a stockholding company. The company's operating segments include private passenger auto insurance, non-standard auto insurance, home and farm insurance, crop insurance, commercial insurance, and others. The company operates only in USA.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.